Cent Eur J Public Health 2008, 16(Supplement):S16-S17

Spontaneously Induced Cellular Immunity to HPV-16/18 and the Therapeutic Vaccination of Patients with HPV-16/18 (Pre-)Malignant Lesions

Sjoerd H. van der Burg
Department of Clinical Oncology, LUMC, Leiden, The Netherlands

Keywords: HPV, carcinoma, cervix, vaccine, immune, T-cells

Published: April 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
van der Burg SH. Spontaneously Induced Cellular Immunity to HPV-16/18 and the Therapeutic Vaccination of Patients with HPV-16/18 (Pre-)Malignant Lesions. Cent Eur J Public Health. 2008;16(Supplement):S16-17.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. De Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, GelukA, et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res. 2002 Jan 15;62(2):472-9.
    2. Welters MJ, de JongA, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S, et al. Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res. 2003 Feb 1;63(3):636-41.
    3. van Poelgeest MI, Nijhuis ER, Kwappenberg KM, Hamming IE, Wouter Drijfhout J, Fleuren GJ, et al. Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. Int J Cancer. 2006 Feb 1;118(3):675-83. Go to original source... Go to PubMed...
    4. Welters MJ, van der Logt P, van den Eeden SJ, Kwappenberg KM, Drijfhout JW, Fleuren GJ, et al. Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. Int J Cancer. 2006 Feb 15;118(4):950-6. Go to original source... Go to PubMed...
    5. Van den Hende M, van Poelgeest MI. Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia. Int J Cancer. In press 2008. Go to original source... Go to PubMed...
    6. De Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ, et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res. 2004 Aug 1;64(15):5449-55. Go to original source... Go to PubMed...
    7. Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007 Jan 1;67(1):354-61. Go to original source... Go to PubMed...
    8. Piersma SJ, Welters MJ, van der Hulst JM, Kloth JN, Kwappenberg KM, Trimbos BJ, et al. Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. Int J Cancer. 2008 Feb 1;122(3):486-94. Go to original source... Go to PubMed...
    9. Van der Burg SH, Piersma SJ, de Jong A, van der Hulst JM, Kwappenberg KM, van den Hende M, et al. Association of cervical cancer with the presence of CD4+ regulatory T-cells specific human papillomavirus antigens. Proc Natl Acad Sci USA. 2007 Jul 17;104(29):12087-92. Spontaneously induced cellular immunity to HPV-16/18 and the therapeutic vaccination of patients with HPV-16/18 (pre-)malignant lesions Sjoerd H. van der Burg Department of Clinical Oncology, LUMC, Leiden, The Netherlands Address for correspondence: S. H. van der Burg, LUMC, Clinical Oncology, Albinusdreef 2, 2333 ZA Leiden, The Netherlands. E-mail: shvdburg@lumc.nl Go to original source... Go to PubMed...
    10. Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol. 2002 Jul 1;169(1):350-8. Go to original source... Go to PubMed...
    11. Vambutas A, DeVoti J, Nouri M, Drijfhout JW, Lipford GB, Bonagura VR, et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides result in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine. 2005 Nov 1;23(45):5271-80. Go to original source... Go to PubMed...
    12. Kenter GG, Welters MJ, ValentijnAR, Lowik MJ, Berends-van der Meer DM, VloonAP, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res. 2008 Jan 1;14(1):169-77. Go to original source... Go to PubMed...
    13. Welters MJ, Kenter GG, Piersma SJ, VloonAP, Löwik MJ, Berends-van der Meer DM, et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 longpeptidesvaccine.ClinCancerRes.2008Jan1;14(1):178-87. Go to original source...

    Return to the content